Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.